Maintenance of patient-reported health-related quality of life post neoadjuvant relugolix prior to the initiation of prostate radiation therapy在开始前列腺放射治疗之前,在新辅助relugolix后维持患者报告的健康相关生活质量FRONTIERS IN ONCOLOGYIF3.32025-01-170OAAI
The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigueFRONTIERS IN ONCOLOGYIF3.32024-08-121OAAI
Impact of neoadjuvant relugolix on patient-reported sexual function and botherFRONTIERS IN ONCOLOGYIF3.32024-04-112OAAI
Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancerFRONTIERS IN ONCOLOGYIF3.32024-03-223OAAI
Impact of Neoadjuvant Relugolix on Patient-Reported Sexual Function and BotherJOURNAL OF SEXUAL MEDICINEIF3.32024-02-050PRE
Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomesFRONTIERS IN ONCOLOGYIF3.32023-11-233OAAI
Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancerFRONTIERS IN ONCOLOGYIF3.32023-10-174OAAI
Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate CancerFRONTIERS IN ONCOLOGYIF3.32022-03-256OAAI
Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate CancerJOURNAL OF SEXUAL MEDICINEIF3.32022-03-171PRE
Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet TherapyFRONTIERS IN ONCOLOGYIF3.32021-09-171OAAI
Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate CancerFRONTIERS IN ONCOLOGYIF3.32021-02-256OAAI
Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate CancerFRONTIERS IN ONCOLOGYIF3.32020-10-292OAAI
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)FRONTIERS IN ONCOLOGYIF3.32020-07-039OAAI
Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)FRONTIERS IN ONCOLOGYIF3.32020-05-0517OAAI
Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)FRONTIERS IN ONCOLOGYIF3.32020-01-225OAAI
Testosterone Recovery Following Short Course Androgen Deprivation Therapy and Stereotactic Body Radiotherapy Correlates Closely with Improvements in Patient-Reported Hormonal and Sexual Domain ScoresINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSIF6.52019-09-012OAAI
Patterns of Recurrence Following Stereotactic Body Radiation Therapy for Localized Prostate CancerINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSIF6.52019-09-010OAAI
Stereotactic Body Radiation Therapy for Unfavorable Prostate Cancer: Large institutional experience.RADIOTHERAPY AND ONCOLOGYIF5.32019-04-010OAAI
Reduced PSA Surveillance Following SBRT for Favorable Prostate Cancer Decreases the Incidence of Anxiety-Promoting Benign PSA Bounces without Limiting the Early Detection of Biochemical FailuresINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSIF6.52018-11-010OAAI
Utilization of Patient-Reported outcomes to Guide symptom Management during stereotactic Body Radiation therapy for Clinically Localized Prostate CancerFRONTIERS IN ONCOLOGYIF3.32017-10-164OAAI